BioSpace News Archive

The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the acquisition of a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (“FortuneBio”).

Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™.

The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a single project manager.

Positron Corporation, a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K submission with the Food and Drug Administration.

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration has approved PYRUKYND® in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia.